- Previous Close
30.75 - Open
30.75 - Bid 30.99 x --
- Ask 31.00 x --
- Day's Range
30.59 - 31.20 - 52 Week Range
22.91 - 41.98 - Volume
4,294,200 - Avg. Volume
8,762,454 - Market Cap (intraday)
15.632B - Beta (5Y Monthly) 0.40
- PE Ratio (TTM)
83.78 - EPS (TTM)
0.37 - Earnings Date --
- Forward Dividend & Yield 0.32 (1.03%)
- Ex-Dividend Date Oct 25, 2024
- 1y Target Est
36.70
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. The company offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. It provides bone polypeptide, oxytocin, heparin sodium, and posterior pituitary injection products; and metformin hydrochloride enteric-coated tablets, glimepiride tablets, calcium dobesilate products, and pioglitazone hydrochloride dispersible tablets. In addition, the company engages in research, development, production, and sales of anti-infective, diabetes, and cardiovascular and cerebrovascular drug; and distributes blood products. The company was formerly known as Boya Bio-pharmaceutical Group Co., Ltd. and changed its name to China Resources Boya Bio-pharmaceutical Group Co.,Ltd. The company was founded in 1993 and is based in Fuzhou City, China.
www.china-boya.comRecent News: 300294.SZ
View MorePerformance Overview: 300294.SZ
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300294.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300294.SZ
View MoreValuation Measures
Market Cap
15.63B
Enterprise Value
10.40B
Trailing P/E
83.78
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.16
Price/Book (mrq)
2.06
Enterprise Value/Revenue
6.09
Enterprise Value/EBITDA
40.13
Financial Highlights
Profitability and Income Statement
Profit Margin
10.90%
Return on Assets (ttm)
3.71%
Return on Equity (ttm)
2.46%
Revenue (ttm)
1.71B
Net Income Avi to Common (ttm)
186.1M
Diluted EPS (ttm)
0.37
Balance Sheet and Cash Flow
Total Cash (mrq)
5.24B
Total Debt/Equity (mrq)
0.06%
Levered Free Cash Flow (ttm)
196.33M